eTheRNA

eTheRNA, a spun out of Belgium’s Vrije Universiteit Brussel, is a clinical-stage biotech company developing innovative immuno-oncology therapies based on its unique APC-activating messenger RNA platform.

eTheRNA has established an integrated set of proprietary capabilities for an end-to-end solution to design, develop and manufacture next-generation mRNA products based on enabling technologies.

eTheRNA was founded in 2013 by Kris Thielemans. The company is headquartered in Antwerpen, Belgium, with an office in New York.

 

eTheRNA has created, eTheRNA’s TriMix platform, a core differentiating component in the Company’s product programs and comprises three mRNAs encoding proteins that act together to significantly increase immune responses.

 

eTheRNA has established an integrated set of proprietary capabilities for an end-to-end solution to design, develop and manufacture next-generation mRNA products based on enabling technologies.

 

eTheRNA will leverage its proprietary molecular designs, lipid biochemistry expertise, customized lipid nanoparticle formulations (cLNPs), mRNA-based T cell adjuvants, and advanced manufacturing processes to overcome the current challenges facing the development of mRNA therapeutics.

 

eTheRNA is backed by Novalis LifeSciences, EQT Life Sciences, PMV, Boehringer Ingelheim Venture Fund, Fund+, Omega Fund, Grand Pharma, BNP Paribas Fortis Private Equity, Kenneth Chien, and others. The company raised €39M in Series B2 round on Aug 23, 2022. This brings eTheRNA's total funding to €98M to date.

 

 

  • Year founded: 2013
  • Funding Info: €98M over 4 Rounds (Latest Funding Type: Series B2)
  • Yearly Revenue: NA
  • Employee Size: 51-200
  • Business Valuation: NA
  • City/Town: Antwerp
  • State: Flemish Region
  • Country: Belgium
Related businesses